Muna Therapeutics and GSK said they will collaborate to identify and validate new therapeutic targets for Alzheimer’s…
Articles by Patricia Inacio, PhD
The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker…
A proof-of-concept Phase 2b clinical trial evaluating the safety and efficacy of Advantage Therapeutics’ investigational immunotherapy AD04 in people with…
Alzamend Neuro is seeking regulatory approval to launch the first U.S. trial of ALZN002, its investigational vaccine for mild…
The U.S. Food and Drug Administration (FDA) has greenlit Annovis Bio to conduct a Phase 2/3 trial to test…
Alpha Cognition’s candidate oral tablet ALPHA-1062, for mild to moderate Alzheimer’s disease, showed efficacy as a…
The U.S. Food and Drug Administration (FDA) has kept to its initial decision to reject a request by Acadia…
A large clinical trial has received $45 million in U.S. funding to evaluate the efficacy of benfotiamine — a lab-made…
ALPHA-1062, Alpha Cognition’s investigational oral tablet for mild to moderate Alzheimer’s disease, may be a bioequivalent substitute for…
Early treatment with crenezumab, an investigational anti-amyloid antibody, failed to significantly slow or prevent cognitive decline in a group…